Claims for Patent: 8,278,033

Summary for Patent: 8,278,033

Title:	Efficient well being assessment and improved treatment protocol
Abstract:	Methods to appraise general health and to assess the effectiveness of therapeutic agents are disclosed. These methods can be performed on blood samples or other bodily fluids and comprise effecting cell death of endothelial cells, staining the dead cells and observing them microscopically. In addition, the invention is directed to combination treatments for neoplastic diseases or other conditions characterized by unwanted angiogenesis by administering an antiangiogenesis agent while maintaining nontoxic levels of ethanol and/or DMSO in the blood.
Inventor(s):	Weisenthal; Larry Mark (Huntington Beach, CA)
Assignee:
Application Number:	12/994,105
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,278,033
Patent Claims:	1. A method to detect and optionally quantify circulating endothelial cells in a vertebrate subject which method comprises (a) contacting body fluid that contains circulating cells obtained from said subject with an antiangiogenic agent so as to render living endothelial cells nonviable; (b) treating the cells with a dye that is excluded by viable cells but taken up by dead cells; and (c) observing the resulting cells under a microscope, and (d) identifying the nonviable endothelial cells in said fluid by their dye-staining, size of about one third that of lymphocytes, angular appearance and intense and refractile color, wherein the body fluid is blood, lymph or plasma. 2. The method of claim 1 wherein the dye is Fast Green. 3. The method of claim 1 wherein the cells are further treated with a dye that stains viable cells. 4. The method of claim 3 wherein said dye that stains viable cells is hematoxylin/eosin (H&E) or Wright-Giemsa. 5. The method of claim 1 which further comprises quantifying the endothelial cells. 6. The method of claim 1 wherein the body fluid is blood or plasma. 7. A method to assess the effectiveness of a therapeutic agent which method comprises comparing the level of circulating endothelial cells in the blood, lymph or plasma of a test subject treated with said agent with either (i) the level of circulating endothelial cells in the blood, lymph or plasma of said subject prior to treating said agent; or (ii) the level of circulating endothelial cells in the blood, lymph or plasma of a control subject not treated with said agent; whereby a decreased level of circulating endothelial cells in the blood, lymph or plasma of said test subject as compared to that in the blood, lymph or plasma of the subject of subparagraphs (i) or (ii) is indicative of effectiveness of said agent, and wherein said assessment is conducted by the method of claim 1. 8. A method to detect and optionally quantify endothelial cells in a tissue which method comprises (a) disaggregating said tissue to obtain a sample that includes any endothelial cells contained therein, (b) treating the sample with an antiangiogenic agent to render living endothelial cells nonviable; (c) treating the sample with a dye that is excluded by viable cells but taken up by dead cells; and (d) observing the cells in the sample under a microscope, and (e) identifying the nonviable endothelial cells in said sample by their dye-staining, size of about one third that of lymphocytes, angular appearance and intense and refractile color. 9. The method of claim 8 wherein said antiangiogenic agent is bevacizumab. 10. The method of claim 8 wherein the dye is Fast Green. 11. The method of claim 8 wherein the cells are further treated with a dye that stains viable cells. 12. The method of claim 11 wherein said dye that stains viable cells is hematoxylin/eosin (H&E) or Wright-Giemsa. 13. The method of claim 8 which further comprises quantifying the endothelial cells. 14. A method to determine the effect of a treatment on viability of endothelial cells in a tissue, which method compromises (a) contacting said tissue comprised of at least viable endothelial cells and natively surrounding viable non-endothelial cells with said treatment to be tested for its effect on endothelial cell viability, (b) if necessary, disaggregating the tissue to obtain a sample containing any endothelial cells without effecting any additional endothelial cell death, (c) treating the sample with a dye that is excluded by viable cells but taken up by dead cells; (d) observing the resulting cells under a microscope, and (e) identifying the nonviable endothelial cells in said sample by their dye-staining, size of about one third that of lymphocytes, angular appearance and intense and refractile color. 15. The method of claim 14 wherein the dye is Fast Green. 16. The method of claim 14 wherein the cells are further treated with a dye that stains viable cells. 17. The method of claim 16 wherein said dye that stains viable cells is hematoxylin/eosin (H&E) or Wright-Giemsa.

Details for Patent 8,278,033

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-03-29